Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)
Tatsunori Shimoi,1 Akihiko Shimomura,1 Tadahiko Shien,2 Yukari Uemura,3 Hiroaki Kato,4 Masahiro Kitada,5 Tatsuya Toyama,6 Tomohiko Aihara,7 Hirofumi Mukai8 1Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; 2Department of Breast and Endocrine Surgery, Okayama...
Main Authors: | Shimoi T, Shimomura A, Shien T, Uemura Y, Kato H, Kitada M, Toyama T, Aihara T, Mukai H |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-02-01
|
Series: | Open Access Journal of Clinical Trials |
Subjects: | |
Online Access: | https://www.dovepress.com/open-label-phase-ii-study-of-everolimus-plus-endocrine-therapy-in-post-peer-reviewed-article-OAJCT |
Similar Items
-
Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
by: Patricia A. Young, MD, et al.
Published: (2021-04-01) -
Obesity as potential breast cancer risk factor for postmenopausal women
by: Swati Sucharita Mohanty, et al.
Published: (2021-03-01) -
Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women—a literature review and proposed guidelines
by: Lauren I. Madigan, et al.
Published: (2020-07-01) -
Abrogating endocrine resistance by targeting ER alpha and PI3K in breast cancer
by: Emily M Fox, et al.
Published: (2012-10-01) -
The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy
by: Jing Xu, et al.
Published: (2023-07-01)